Logistics giants pivot to cold-chain infrastructure for GLP-1 surge

The rapid adoption of weight-loss and diabetes injections has turned pharmaceutical logistics into a high-stakes race. Because drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound require strict temperature control, any lapse in the supply chain renders the medicine ineffective. The Food and Drug Administration has explicitly warned patients to reject any shipments that arrive warm, placing intense pressure on carriers to guarantee end-to-end refrigeration.

Legacy shipping companies are responding with massive capital injections to capture the growing market. UPS recently committed $48 million to expand its temperature-controlled facility network, aiming to secure a foothold in a sector where demand for biologics is projected to reach $39.1 billion by 2033. This shift mirrors the heightened focus on medical logistics that emerged during the pandemic, transforming temperature-sensitive shipping from a niche service into a primary pillar of the global pharmaceutical supply chain.